Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome

被引:210
|
作者
Rassen, Jeremy A. [1 ]
Choudhry, Niteesh K.
Avorn, Jerry
Schneeweiss, Sebastian
机构
[1] Harvard Univ, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med,Med Sch, Boston, MA 02120 USA
基金
美国国家卫生研究院; 美国医疗保健研究与质量局;
关键词
clopidogrel; drugs; myocardial infarction; platelets; proton pump inhibitors; revascularization; ACUTE MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; ANTIPLATELET ACTION; CONTROLLED TRIAL; ASPIRIN; THERAPY; RISK; RESISTANCE; EVENTS; DRUGS;
D O I
10.1161/CIRCULATIONAHA.109.873497
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Recent studies have raised concerns about the reduced efficacy of clopidogrel when used concurrently with proton pump inhibitors (PPIs), but those studies may have overestimated the risk. Methods and Results-We studied the potential for increased risk of adverse cardiovascular events among users of clopidogrel with versus without concurrent use of PPIs in 3 large cohorts of patients >= 65 years of age, treated between 2001 and 2005. All patients had undergone percutaneous coronary intervention or had been hospitalized for acute coronary syndrome in Pennsylvania, New Jersey, or British Columbia, and subsequently had initiated treatment with clopidogrel. We recorded myocardial infarction hospitalization, death, and revascularization among PPI users and nonusers. We assessed our primary end point of myocardial infarction hospitalization or death using cohort-specific and pooled regression analyses. We entered 18 565 clopidogrel users into our analysis. On a pooled basis, 2.6% of those who also initiated a PPI versus 2.1% of PPI nonusers had a myocardial infarction hospitalization; 1.5% versus 0.9% died; and 3.4% versus 3.1% underwent revascularization. The propensity score-adjusted rate ratio for the primary end point of myocardial infarction or death was 1.22 (95% confidence interval, 0.99 to 1.51); for death, 1.20 (95% confidence interval, 0.84 to 1.70); and for revascularization, 0.97 (95% confidence interval, 0.79 to 1.21). Matched analyses generally yielded similar results. Conclusions-Although point estimates indicated a slightly increased risk of myocardial infarction hospitalization or death in older patients initiating both clopidogrel and a PPI, we did not observe conclusive evidence of a clopidogrel-PPI interaction of major clinical relevance. Our data suggest that if this effect exists, it is unlikely to exceed a 20% risk increase. (Circulation. 2009; 120: 2322-2329.)
引用
收藏
页码:2322 / U34
页数:11
相关论文
共 50 条
  • [1] Response to Letter Regarding Article, "Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome"
    Rassen, Jeremy A.
    Choudhry, Niteesh K.
    Avorn, Jerry
    Schneeweiss, Sebastian
    CIRCULATION, 2010, 122 (05) : 415 - 415
  • [2] Letter by Potter and Le Lorier Regarding Article, "Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome"
    Potter, Brian J.
    Le Lorier, Jaques
    CIRCULATION, 2010, 122 (05) : E414 - E414
  • [3] Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan
    Lin, Chen-Fang
    Shen, Li-Jiuan
    Wu, Fe-Lin Lin
    Bai, Chyi-Huey
    Gau, Churn-Shiouh
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (05) : 824 - 834
  • [4] Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome
    Gaspar, Antonio
    Ribeiro, Silvia
    Nabais, Sergio
    Rocha, Sergia
    Azevedo, Pedro
    Pereira, Miguel Alvares
    Brandao, Aida
    Salgado, Alberto
    Correia, Adelino
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2010, 29 (10) : 1511 - 1520
  • [5] Effect of Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention
    Banerjee, Subhash
    Weideman, Rick A.
    Weideman, Mark W.
    Little, Bertis B.
    Kelly, Kevin C.
    Gunter, Jennifer T.
    Tortorice, Kathryn L.
    Shank, Michelle
    Cryer, Byron
    Reilly, Robert F.
    Rao, Sunil V.
    Kastrati, Adnan
    de Lemos, James A.
    Brilakis, Emmanouil S.
    Bhatt, Deepak L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 107 (06): : 871 - 878
  • [6] Clopidogrel loading dose and cardiovascular outcomes in acute coronary syndrome patients who undergo percutaneous coronary intervention
    Wang, C
    He, J
    Bae, JP
    McCollam, PL
    Griffin, BT
    VALUE IN HEALTH, 2005, 8 (06) : A97 - A98
  • [7] Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention
    Lee, Dongyoung
    Kim, Je Sang
    Kim, Beom Jin
    Shin, Seung Yong
    Kim, Dong Bin
    Ahn, Hyung Sik
    MEDICINE, 2021, 100 (52)
  • [8] Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention
    Nakayama, Atsuko
    Morita, Hiroyuki
    Ando, Jiro
    Fujita, Hideo
    Ohtsu, Hiroshi
    Nagai, Ryozo
    HEART AND VESSELS, 2013, 28 (03) : 292 - 300
  • [9] Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention
    Atsuko Nakayama
    Hiroyuki Morita
    Jiro Ando
    Hideo Fujita
    Hiroshi Ohtsu
    Ryozo Nagai
    Heart and Vessels, 2013, 28 : 292 - 300
  • [10] Clopidogrel loading dose and cardiovascular outcomes in acute coronary syndrome patients who undergo percutaneous coronary intervention.
    Wang, C
    He, JM
    Bae, JP
    McCollam, PL
    Griffin, BT
    PHARMACOTHERAPY, 2005, 25 (10): : 1475 - 1475